CMIC CMO USA Corporation is a member of the CMIC Group, a company with facilities in 8 countries and over 5900 employees worldwide. Our FDA-registered facility is located in Central New Jersey. We specialize in the formulation development and GMP commercial manufacturing of NDA and ANDA solid dosage products with expertise in sustained and controlled release products. We will guide you towards regulatory approval and commercial launch while also helping you reduce your development cycles and capital costs.
James E. Gregory, UPM Pharmaceuticals||October 7, 2015 Pharmaceutical and biopharmaceutical companies large and small are increasingly relying on third-party providers for support at all stages of drug development. To realize efficiencies, they are at the same time reducing the number of suppliers to a preferred few with whom they can form strategic partnerships.
Franklin Spriggs, Stephanie Mowery and Bo Kowalcyk, AIT Bioscience ||October 7, 2015 ADCs are a breakthrough cancer treatment that can deliver cytotoxins directly to cancer cells without the sweeping collateral damage of traditional chemotherapy.
Suhasini Sharma, Sciformix Corporation ||September 11, 2015 Global biologics market will expand to $250 billion annually by 2020, with biosimilars and non-original biologics commanding 4-10% of that market